Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M T Lotze

Showing results (161-170 of 242) with videos related to

Pageof 25
Sort By:
Cancer Research|April 1, 1984
In vivo administration of purified Jurkat-derived interleukin 2 in miceJ H Donohue, M T Lotze, R J Robb, et al.
Gene Therapy|August 18, 2001
Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cellsH Okada, L Villa, J Attanucci, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1989
In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing miceJ K McIntosh, D M Jablons, J J Mulé, et al.
The Journal of Allergy and Clinical Immunology|November 1, 1992
The effect of IL-4 on human nasal mucosal responsesB E Emery, M V White, Y Igarashi, et al.
European Journal of Immunology|July 31, 1999
CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growthC Esche, A Gambotto, Y Satoh, et al.
Human Immunology|March 1, 1981
HLA-DR characterization of a Chippewa Indian subpopulation with high prevalence of rheumatoid arthritisW B Bias, S H Hsu, M K Pollard, et al.
Cancer Gene Therapy|June 1, 1995
Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alphaK Nishihara, R F Barth, N Wilkie, et al.
Stem Cells (Dayton, Ohio)|January 1, 1997
Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccinesJ I Mayordomo, T Zorina, W J Storkus, et al.
Cancer|December 15, 1986
Clinical effects and toxicity of interleukin-2 in patients with cancerM T Lotze, Y L Matory, A A Rayner, et al.
Annals of Surgery|October 1, 1989
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patientsS A Rosenberg, M T Lotze, J C Yang, et al.
Pageof 25

Showing results (161-170 of 242) with videos related to

Sort By:
Pageof 25
Cancer Research|April 1, 1984
In vivo administration of purified Jurkat-derived interleukin 2 in miceJ H Donohue, M T Lotze, R J Robb, et al.
Gene Therapy|August 18, 2001
Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cellsH Okada, L Villa, J Attanucci, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1989
In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing miceJ K McIntosh, D M Jablons, J J Mulé, et al.
The Journal of Allergy and Clinical Immunology|November 1, 1992
The effect of IL-4 on human nasal mucosal responsesB E Emery, M V White, Y Igarashi, et al.
European Journal of Immunology|July 31, 1999
CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growthC Esche, A Gambotto, Y Satoh, et al.
Human Immunology|March 1, 1981
HLA-DR characterization of a Chippewa Indian subpopulation with high prevalence of rheumatoid arthritisW B Bias, S H Hsu, M K Pollard, et al.
Cancer Gene Therapy|June 1, 1995
Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alphaK Nishihara, R F Barth, N Wilkie, et al.
Stem Cells (Dayton, Ohio)|January 1, 1997
Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccinesJ I Mayordomo, T Zorina, W J Storkus, et al.
Cancer|December 15, 1986
Clinical effects and toxicity of interleukin-2 in patients with cancerM T Lotze, Y L Matory, A A Rayner, et al.
Annals of Surgery|October 1, 1989
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patientsS A Rosenberg, M T Lotze, J C Yang, et al.
Pageof 25